<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746263</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14504054</org_study_id>
    <nct_id>NCT02746263</nct_id>
  </id_info>
  <brief_title>Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Repeated Dose, Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain in Combination With Patient-Controlled Analgesia With Morphine in Adults Following Elective Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare intravenous (IV) and oral acetaminophen for the
      treatment of acute moderate to severe pain in combination with standard patient-controlled
      analgesia (PCA) in adult subjects following total knee replacement.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision because enrollment was slower than expected
  </why_stopped>
  <start_date type="Actual">April 27, 2016</start_date>
  <completion_date type="Actual">May 5, 2016</completion_date>
  <primary_completion_date type="Actual">May 5, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity on a Numerical Pain Scale (NPS) for 18 Hours</measure>
    <time_frame>18 hours</time_frame>
    <description>Participants rate intensity of their pain on a Numerical Pain Scale (NPS) from 0-10, wherein 0=no pain (better) and 10=most intense pain (worse). The highest possible score is 10.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Acute Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>IV acetaminophen/Morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV acetaminophen 1000 mg every 6 hours over 18 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral acetaminophen/Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV acetaminophen</intervention_name>
    <arm_group_label>IV acetaminophen/Morphine</arm_group_label>
    <other_name>Ofirmev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral acetaminophen</intervention_name>
    <arm_group_label>Oral acetaminophen/Morphine</arm_group_label>
    <other_name>Acetaminophen (APAP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Patient controlled analgesia</description>
    <arm_group_label>IV acetaminophen/Morphine</arm_group_label>
    <arm_group_label>Oral acetaminophen/Morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be adequately informed and understand the nature and risks of the study
             and must be able to provide a signature and date on the informed consent form.

          2. Subject must be male or females, between 50 and 90 years of age (inclusive) at
             Screening.

          3. Subject must have a weight range of 50 to 120 kg.

          4. Subject must be in a American Society of Anesthesiologists risk class of I, II, or
             III.

          5. Subject must have successfully completed an unilateral uncomplicated total knee
             replacement surgery, able to take oral medication, and report having moderate to
             severe acute pain as determined by a pain score ≥ 5 from the 11-point Numeric Pain
             Rating Scale (NPRS) scale during the period of 3 to 6 hours postsurgery.

          6. Female subjects of child-bearing potential must have a negative serum pregnancy test
             at the Screening and day-of-surgery.

          7. Subjects must be able to communicate effectively with study personnel.

          8. Subject must be able and willing to follow all protocol requirements, including
             operating a PCA device, and study restrictions.

        Exclusion Criteria:

          1. Subject is from a vulnerable population, as defined by the Code of Federal Regulations
             Title 45, Part 46, 1. Section 46.111(b), including but not limited to employees
             (temporary, part-time, full time, etc.) or a family member of the research staff
             conducting the study, or of the sponsor, or of the clinical research organization, or
             of the Institutional Review Board.

          2. Subject has an oxygen saturation of less than 95% while awake on room air.

          3. Subject has a positive test result for human immunodeficiency virus, hepatitis B
             (surface antigen), or hepatitis C virus antibody at Screening.

          4. Subject has used an average of 30 mg oral morphine equivalents or greater, 1 to 2
             weeks prior to the day of surgery. Subjects who, in the investigator's opinion are
             developing opioid tolerance will be excluded.

          5. Subject has a history of any drug allergy, hypersensitivity, or intolerance to
             acetaminophen or morphine or to any of the excipients in the IV or oral formulations
             used.

          6. Subject has intra- or postoperative complications, which in the view of the
             investigator, makes the subject unsuitable for the participation of the study.

          7. Subject has received neuraxial (spinal or epidural) opioid injected perioperatively.

          8. Subject has received a local anesthetic, regional, or wound injection or continuous
             infusion by any route.

          9. Subject has impaired liver function (eg, aspartate aminotransferase, alanine
             aminotransferase, or bilirubin greater than or equal to 3.0 times the upper limit of
             normal), active hepatic disease, evidence of clinically significant liver disease, or
             other condition (eg, alcoholism, cirrhosis, or hepatitis) that suggests the potential
             for an increased susceptibility to hepatic toxicity with study drug exposure.

         10. Subject has renal dysfunction or is at risk for renal failure due to volume depletion.

         11. Subject has donated or had significant loss of whole blood (480 mL or more) within 30
             days, or plasma within 14 days prior to dosing.

         12. Subject has had any major surgery within 3 months prior to day-of-surgery.

         13. Subject has a history of acute illness within 14 days prior to day-of-surgery.

         14. Subject has participated in another clinical study within 30 days prior to
             day-of-surgery or plans to participate in another clinical study while concurrently
             enrolled in this study.

         15. Subject has a history of conditions which might be specifically contraindicated or
             require caution to be used during the administration of any drug in the study.

         16. Subject has any other medical, psychiatric and/or social reason for exclusion as
             determined by the investigator.

         17. Subject has a positive test result for drugs of abuse (amphetamines, barbiturates,
             benzodiazepines, cannabinoids [including medical use of marijuana], cocaine,
             methamphetamine, methadone, or methylenedioxy-methamphetamine) at Screening. Subjects
             with a positive test result for prescribed drugs may be included in the study at the
             discretion of the investigator. Subjects with a positive test result for cannabinoids
             with a prescription for medical marijuana will be excluded from the study, subjects
             with a prescription for dronabinol (∆-9-tetrahydrocannabinol) may be included at the
             discretion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pensacola Research Consultants</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University, Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <results_first_submitted>October 17, 2019</results_first_submitted>
  <results_first_submitted_qc>October 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2019</results_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elective total knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IV Acetaminophen/Morphine</title>
          <description>IV acetaminophen 1000 mg every 6 hours over 18 hours
IV acetaminophen
Morphine: Patient controlled analgesia</description>
        </group>
        <group group_id="P2">
          <title>Oral Acetaminophen/Morphine</title>
          <description>Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
Oral acetaminophen
Morphine: Patient controlled analgesia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per Protocol Analysis Set - The single participant enrolled was in violation of the protocol, leading to unreliable or uninterpretable data.</population>
      <group_list>
        <group group_id="B1">
          <title>IV Acetaminophen/Morphine</title>
          <description>IV acetaminophen 1000 mg every 6 hours over 18 hours
IV acetaminophen
Morphine: Patient controlled analgesia</description>
        </group>
        <group group_id="B2">
          <title>Oral Acetaminophen/Morphine</title>
          <description>Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
Oral acetaminophen
Morphine: Patient controlled analgesia</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity on a Numerical Pain Scale (NPS) for 18 Hours</title>
        <description>Participants rate intensity of their pain on a Numerical Pain Scale (NPS) from 0-10, wherein 0=no pain (better) and 10=most intense pain (worse). The highest possible score is 10.</description>
        <time_frame>18 hours</time_frame>
        <population>Per Protocol Analysis Set - The single participant enrolled was in violation of the protocol, leading to unreliable or uninterpretable data.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen/Morphine</title>
            <description>IV acetaminophen 1000 mg every 6 hours over 18 hours
IV acetaminophen
Morphine: Patient controlled analgesia</description>
          </group>
          <group group_id="O2">
            <title>Oral Acetaminophen/Morphine</title>
            <description>Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
Oral acetaminophen
Morphine: Patient controlled analgesia</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity on a Numerical Pain Scale (NPS) for 18 Hours</title>
          <description>Participants rate intensity of their pain on a Numerical Pain Scale (NPS) from 0-10, wherein 0=no pain (better) and 10=most intense pain (worse). The highest possible score is 10.</description>
          <population>Per Protocol Analysis Set - The single participant enrolled was in violation of the protocol, leading to unreliable or uninterpretable data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 days</time_frame>
      <desc>Number of participants at risk for All-Cause Mortality, Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) are all 0 for the intravenous acetaminophen arm because no participants were enrolled into that arm. All non-serious AEs are reported for the single subject enrolled into the oral acetaminophen arm (including opioid AEs).</desc>
      <group_list>
        <group group_id="E1">
          <title>IV Acetaminophen/Morphine</title>
          <description>IV acetaminophen 1000 mg every 6 hours over 18 hours
IV acetaminophen
Morphine: Patient controlled analgesia</description>
        </group>
        <group group_id="E2">
          <title>Oral Acetaminophen/Morphine</title>
          <description>Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
Oral acetaminophen
Morphine: Patient controlled analgesia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute blood loss anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Intermittent thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Intermittent leucocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Stress hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Suspicion of adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Postoperative pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diffuse bronchial wall thickening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small number of participants analyzed.
The single participant enrolled was in violation of the protocol, leading to unreliable or uninterpretable data.
All AEs were listed, but not related to the study drug.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Mallinckrodt Pharmaceuticals</organization>
      <phone>800-556-3314</phone>
      <email>clinicaltrials@mnk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

